Filing Details

Accession Number:
0001209191-19-041936
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-07-12 16:27:04
Reporting Period:
2019-07-10
Accepted Time:
2019-07-12 16:27:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
921299 Fibrogen Inc FGEN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1623238 B Thomas Neff C/O Fibrogen, Inc.
409 Illinois St.
San Francisco CA 94158
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-07-10 6,834 $2.90 2,425,974 No 4 M Direct
Common Stock Disposition 2019-07-10 12,167 $44.66 2,413,807 No 4 S Direct
Common Stock Disposition 2019-07-10 6,233 $45.07 2,407,574 No 4 S Direct
Common Stock Disposition 2019-07-10 1,418 $44.81 54,164 No 4 S Indirect By Family Partnership
Common Stock Acquisiton 2019-07-11 6,834 $2.90 2,414,408 No 4 M Direct
Common Stock Disposition 2019-07-11 17,900 $45.14 2,396,508 No 4 S Direct
Common Stock Disposition 2019-07-11 500 $45.66 2,396,008 No 4 S Direct
Common Stock Disposition 2019-07-11 1,418 $45.09 52,746 No 4 S Indirect By Family Partnership
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Indirect By Family Partnership
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Indirect By Family Partnership
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2019-07-10 6,834 $0.00 6,834 $2.90
Common Stock Stock Option (Right to Buy) Disposition 2019-07-11 6,834 $0.00 6,834 $2.90
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
225,540 2020-06-09 No 4 M Direct
218,706 2020-06-09 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 20,000 Indirect By Spouse
Common Stock 60,946 Indirect See footnote
Footnotes
  1. Shares sold pursuant to a 10b5-1 plan.
  2. The shares were sold at prices ranging from $44.035 to $44.99. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. The shares were sold at prices ranging from $45.00 to $45.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  4. The shares were sold at prices ranging from $44.23 to $45.13. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  5. The shares were sold at prices ranging from $44.56 to $45.52. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  6. The shares were sold at prices ranging from $45.60 to $45.69. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  7. The shares were sold at prices ranging from $44.55 to $45.34. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  8. The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
  9. Fully vested.